Financial Investments for Development of Innovative Amniotic Membrane

Global attention has been witnessing a shift from manufacturing of synthetic drugs to evaluating opportunities for generating medicines from one’s own tissues and stem cells. Research has been indicating longer sustainability of these therapies over other traditional treatments. Various efforts are being undertaken in this regard and some include:

• Formation of regulations on regenerative therapies including amniotic membrane/tissue-based products in Japan in November 2014 

• Offering of in-house resources for stem cell/amniotic membrane production, including equipment and facilities, information systems, and placenta-derived amniotic membrane preservation services by conglomerates such as MiMedx and Integra LifeSciences Corporation

• Companies are proposing for conditional approval of regenerative therapies

Innovation in amniotic membrane development program is sponsored by various leading manufacturers that focus on empowering the amniotic membrane product advancements in the near future. The objective of such financial investments is to offer funding to the health professionals pursuing innovative ideas for advancements in regenerative medicine (amniotic membrane products). For instance, amniotic tissue-based products of TissueTech, Inc., a leader in regenerative medicine find major applications in ophthalmology. The National Institute of Health (NIH) has been offering TissueTech with research grants for more than 25 years. Also, in 2015, Mercia Fund Management offered US$ 438,636.8 to NuVision - University of Nottingham in order to support commercialization of NuVision's amniotic membrane-derived biological bandage, Omnigen that is used to used to treat ocular wounds.

Rising number of deaths due to cancers, and growing number of patients in ophthalmology has been promoting research interest in regenerative therapies such as amniotic membranes for treating these diseases. The U.S. FDA noted that more than 33% of the clinical trials in regenerative therapies were in the field of oncology as of Q1 2015, closely followed by eye diseases. There were 486 clinical trials underway in Q1 2015, out of which 180 were in phase    I, around 288 in phase II and 48 in phase III. Continued collaborative research interest along with increased funding is expected to create unique opportunities for both small- and large-scale amniotic membrane manufacturers over the long run.

Being at the early stage of commercialization, amniotic membranes exhibit lucrative investment opportunities from government, regional governing bodies and private companies. For example, the European Commission had contributed EUR 249.6 Mn to 37 stem cell research projects over 2007–12, through the health and SME streams of its foreign policy. In the U.S., seven federal agencies are continually investing in stem cell research for the development of strategic medicines in the field of nuclear defense, nonproliferation and naval research. 

Availability of a wide range of applications of amniotic membrane  Growing probability of availability of reimbursements for such premium-priced amniotic membrane-based treatments is also expected to contribute largely to growing adoption among patients. The trend is being witnessed in both high- and middle-income countries, owing to rising personal disposable income levels.

North America accounted for the largest market share in 2019, due to increasing number of tissue banks in North America. Increasing research and development activities, is another important factor, which can increase the growth of the opthalmology amniotic membrane market

Increasing healthcare awareness among the people, is expected to boost the growth of the opthalmology amniotic membrane market. Also, increasing prevalence of eye disorders and increasing government funding for research and development activities, are the major factors, responsible for the growth of opthalmology amniotic membrane market.  The number of amniotic transplantation procedures are increasing, which can boost the growth of global opthalmology amniotic membrane market. 

The major players in the opthalmology amniotic membrane market includes MiMedx Group, Inc., Skye Biologics Inc., Alliqua BioMedical, Inc., Alliqua BioMedical, Inc., Human Regenerative Technologies, LLC, Integra LifeSciences Holdings Corp. etc. The success of amniotic membrane for the treatment of ocular surface disease due to its anti-inflammatory, antifibrotic, and antiangiogenic  properties, are expected to increase the demand of amniotic membrane products for the treatment of eye diseases. Collaborative research is an ongoing trend in the amniotic membrane market, especially in Europe, which is expected to increase the growth of the opthalmology amniotic membrane market. Multi-center trials and placenta-derived amnion allografts is gaining popularity in Europe.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com